LOGIN  |  REGISTER
Cue Biopharma

scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

May 01, 2025 | Last Trade: US$5.52 0.01 -0.18

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

  • The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.
  • Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings Only
  • H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET.

A webcast of the presentations can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page